This federal Project Grant award from the National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $895,538 to support research to develop more effective oral treatment regimens for Mycobacterium abscessus pulmonary disease. The project aims to discover antibacterial drug combinations that can rapidly reduce bacterial burden and overcome the limited immune response in affected patients. Key objectives include proposing optimized drug regimens with the greatest potential for bacterial clearance, characterizing the mechanisms of drug-induced bacterial cell death, and identifying determinants of drug resistance to inform future treatment development. This multidisciplinary research effort, led by HMH Hospitals Corporation (doing business as Hackensack University Medical Center), is expected to run from January 2025 through December 2029.
Generated 3/4/25, 6:07 AM